In this insightful interview, Dr. Susan Zhang, Executive Medical Director at Pfizer, joins Emma Ter-Azaryan, YouTube Content Coordinator of OncoDaily, to discuss her groundbreaking work in oncology and the recent success of the BRAF-TOVI and MEKTOVI treatments for BRAF-mutant metastatic colorectal cancer.
Key Highlights:
- Dr. Zhang’s inspiring transition from clinical medicine to drug development at Pfizer
- The challenges faced in the Breakwater Study, from drug safety to enrolling patients with rare biomarkers
- The future of colorectal cancer therapies at Pfizer, focusing on innovation in biomarker testing and personalized treatment options
- The potential of liquid biopsy in advancing cancer diagnostics and treatment